Literature DB >> 19127071

Validation study of the OHIO Chamber in patients with Japanese cedar pollinosis.

Kazuhiro Hashiguchi1, Huaipeng Tang, Toshio Fujita, Kiyochika Suematsu, Shigekazu Tsubaki, Hitoshi Nagakura, Sei Kitajima, Minoru Gotoh, Kimihiro Okubo.   

Abstract

BACKGROUND: An artificial exposure chamber (OHIO Chamber), which allows dispersal of a fixed concentration of Japanese cedar (JC) pollen under stable conditions, was constructed. This study was conducted to identify the exposure conditions assuring validity of the clinical tests conducted using this chamber.
METHODS: Twenty-four adult patients with JC pollinosis were exposed to different concentrations of JC pollen: 0 (only during the summer period), 4,000, 8,000 and 12,000 grains/m3, and the nasal and ocular symptoms were self-assessed during a 4-hour period of exposure. The amount of nasal discharge was measured and the sneezing frequency was recorded. This study was conducted twice during the summer and winter periods, i.e. non-pollen seasons. The reproducibility of the symptoms between the two seasons was assessed.
RESULTS: None of the subjects developed any symptom at the pollen concentration of 0 grains/m3. No significant differences in the time to the onset of symptoms were found between the summer and winter study, regardless of the pollen concentration. There were no significant differences between the summer and winter study in the total symptom score and total nasal symptom score at any pollen concentration, suggesting the very favorable reproducibility of symptoms.
CONCLUSIONS: Efficient and reproducible results are obtained in patients exposed to JC pollen in the OHIO Chamber. The results suggest the conditions of JC pollen exposure have scientific validity and the OHIO Chamber has the potential to contribute significantly to basic and clinical studies of JC pollinosis. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127071     DOI: 10.1159/000189197

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

1.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

2.  Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber.

Authors:  Shuichiro Endo; Minoru Gotoh; Kimihiro Okubo; Kazuhiro Hashiguchi; Hidenori Suzuki; Keisuke Masuyama
Journal:  J Drug Assess       Date:  2012-06-17

3.  Efficacy of fluticasone furoate nasal spray and levocetirizine in patients with Japanese cedar pollinosis subjected to an artificial exposure chamber.

Authors:  Kazuhiro Hashiguchi; Sho Kanzaki; Ken-Ichiro Wakabayashi; Nobuaki Tanaka; Kayoko Kawashima; Kiyochika Suematsu; Shoji Tokunaga; Kaoru Ogawa; Kimihiro Okubo
Journal:  J Drug Assess       Date:  2013-07-26

4.  Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure.

Authors:  Sho Kanzaki; Kazuhiro Hashiguchi; Ken-Ichiro Wakabayashi; Kiyochika Suematsu; Kimihiro Okubo
Journal:  J Drug Assess       Date:  2016-09-27

5.  Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study.

Authors:  Kei Hosoya; Satoru Masuno; Kazuhiro Hashiguchi; Kimihiro Okubo
Journal:  J Drug Assess       Date:  2014-09-03

6.  Technical and clinical validation of an environmental exposure unit for ragweed.

Authors:  Paul J Gomes; Keith J Lane; Endri Angjeli; Linda Stein; Mark B Abelson
Journal:  J Asthma Allergy       Date:  2016-12-14

7.  The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber.

Authors:  Kazuhiro Hashiguchi; Kimihiro Okubo; Ken-Ichiro Wakabayashi; Nobuaki Tanaka; Yukiko Watada; Kiyochika Suematsu; Minoru Gotoh
Journal:  J Drug Assess       Date:  2012-10-09

8.  Evaluation of Montelukast for the Treatment of Children With Japanese Cedar Pollinosis Using an Artificial Exposure Chamber (OHIO Chamber).

Authors:  Kazuhiro Hashiguchi; Kimihiro Okubo; Yoichi Inoue; Hirotaka Numaguchi; Kumi Tanaka; Nobuyuki Oshima; Anish Mehta; Chisato Nishida; Itori Saito; George Philip
Journal:  Allergy Rhinol (Providence)       Date:  2018-07-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.